---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-058017"
form_type: "8-K"
ticker: "RIGL"
cik: "0001034842"
company_name: "RIGEL PHARMACEUTICALS INC"
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T15:33:27.372466+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Rigel Q1 2024 revenue $29.5M, net loss $8.2M; acquires GAVRETO, appoints CMO

## Summary
- TAVALISSE net sales $21.1M (down from $22.3M) but bottles shipped hit highest quarterly level since launch.
- REZLIDHIA net sales $4.9M, up from $1.5M YoY, driven by increased demand.
- Net loss improved to $8.2M ($0.05/sh) from $13.5M ($0.08/sh) in Q1 2023.
- Acquired U.S. rights to GAVRETO (pralsetinib) for RET fusion-positive NSCLC/thyroid cancer; transition expected July 2024.
- Cash and short-term investments $49.6M at March 31, 2024; credit facility amendment extended maturity by one year.

## SEC filing metadata
- accession: 0001104659-24-058017
- form_type: 8-K
- ticker: RIGL
- cik: 0001034842
- company_name: RIGEL PHARMACEUTICALS INC
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1034842/000110465924058017/0001104659-24-058017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1034842/000110465924058017/tm2413689d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-058017
- JSON: https://secwatch.observer/filing/0001104659-24-058017.json
- Plain text: https://secwatch.observer/filing/0001104659-24-058017.txt

## Key facts
- Earnings Releases
  RIGEL PHARMACEUTICALS INC reported first quarter ended March 31, 2024 results: revenue $29.5 million.
  - Period: first quarter ended March 31, 2024
  - Revenue: $29.5 million
  - Result: reported results
  source text: 2 tm2413689d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Rigel Reports First Quarter 2024 Financial Results and Provides Business Update · First quarter 2024 total revenue of $29.5 million, which includes TAVALISSE ® net product sales of $21.1 million and REZLIDHIA ® net product sales of $4.9 million · Expanded Rigel's portfolio with acquisition of GAVRETO ® , a
  evidence_url: https://www.sec.gov/Archives/edgar/data/1034842/000110465924058017/0001104659-24-058017-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.